Gladstone Home blank GIVI HOME
 
spacer
 
Supporting Gladstone
Past Contributions
  • Discovery that Apobec3 encodes Rfv3, a gene influencing production of neutralizing antibody responses in retrovirus infection. Science 321:1343–1346, 2008.

  • Studies revealing the regulation of APOBEC3G expression and complex formation in various primary immune cells. J. Biol. Chem. 282:3539–3546, 2007.

  • Discovery that HIV-1 virions transmitted in trans from dendritic cells to T cells principally originate from the surface of DCs, except during antigen recognition, when some internalized virions may also be transmitted to the antigen specific T cells. PLoS Path. 3:e4, 2007.

  • Demonstration that ABOBEC3G, in conjunction with RNA granules, functions to regulate endogenous mobile genetic elements (e.g., Alu RNAs), whose mobility contributes to a variety of human diseases including cancers and leukemias. Proc. Natl. Acad. Sci. 103:15588-15593, 2006.

  • Studies revealing the regulation of APOBEC3G expression and complex formation in various primary immune cells. J. Biol. Chem. 282:3589–3546, 2007.

  • Demonstration that laboratory-adapted CCR5-tropic 81A virions fuse rapidly and efficiently to immature MDDCs, whereas NL4-3, the isogenic CXCR4-tropic counterpart of 81A, fuse slowly and inefficiently to both immature and mature MDDCs. J. Virol. 80:1992–1999, 2006.

  • Identification of NF-kB as a modulator of inhibitory tone in the brain by regulating expression of GAD65 in inhibitory GABAergic interneurons. Mol. Cell Biol. 26:7283–7298, 2006.

  • Illustration that A3G postentry restriction of HIV infection in peripheral lymphocytes is overcome by secreted factors in lymphoid tissues. J. Exp. Med. 203:865–870, 2006.

  • Discovery of NF-kB p50/HDAC1 as a transcriptionally repressive complex promoting HIV-1 latency. EMBO J. 25:139–149, 2006.

  • Demonstration of the regulation of NF-kB RelA acetylation by phosphorylation of neighboring tyrosine residues. Mol. Cell. Biol. 25:7966–7975, 2005.

  • Identification of HIV Nef association with cellular immunological synapses and modulation of T-cell signaling. J. Immunol. 175:6050–6057, 2005.

  • Discovery of APOBEC3G as a post-entry restriction factor for HIV in resting CD4 T cells. Nature 435:108–114, 2005.

  • Novel studies detailing HIV virion fusion. Virology 328:36–44, 2004.

  • Description of NF-kB as an inducible antagonist of HIV latency. J. Biol. Chem. 279:42008–42017, 2004.

  • Studies revealing how the HIV Vif protein defeats the powerful antiviral action of the APOBEC3G enzyme present in CD4 T lymphocytes and macrophages. Mol. Cell 12:591–601, 2003.

  • Demonstration that HIV Vif depletes intracellular levels of the innate antiviral enzyme, APOBEC3G, by both partially blocking the translation of APOBEC3G mRNA and accelerating the intracellular turnover of the APOBEC3G protein by targeting this enzyme for destruction in the 26S proteasome. Mol. Cell 12:591–601, 2003.

  • Development of a new assay permitting the study of fusion of actual HIV-1 virions to biologically relevant target cells including primary CD4 T cells present in human tonsil and spleen tissue. Nat. Biotech. 20:1151–1154, 2002.

  • Description of how acetylation at three different sites within the RelA subunit of the NF-kB transcription factor complex modulates different biological functions including DNA binding, transcriptional activation, and assembly with its inhibitor, IkBa. EMBO J.21:6539–6548, 2002.

  • Demonstration that HIV-1 Vpr induces dynamic disruption in nuclear envelope architecture and integrity through effects on nuclear lamina. Science 294:1105–1108, 2001.

  • Description of the regulation of nuclear NF-kB action by reversible acetylation. Science 293:1653–1657, 2001.

  • Identification of anti-apoptotic effects of HIV Nef mediated through assembly with and inhibition of ASK1. Nature 410:834–838, 2001.

  • Description of co-translational biogenesis of NF-kB p50 by the 26S proteasome. Cell 92:819–828, 1998.

  • Description of general 'trigger-driver' model for cytokine receptor organization. Proc. Natl. Acad. Sci. USA 93:231–235, 1996.

  • Demonstration that IL-2 signaling leads to activation of STAT 5. Proc. Natl. Acad. Sci. USA 92:7192–7196, 1995.

  • Demonstration that c-Rel is expressed later that Rel A and inhibits Rel A activation of the HIV-1 LTR. Proc. Natl. Acad Sci. USA 90:1023–1027, 1993.

  • Demonstration that IkB is degraded in a signal coupled manner and that nuclear NF-kB activates the IkB gene expression revealing an auto-regulatory loop that resets this intracellular signaling system. Science 259:1912–1915, 1993.

  • Identification of a novel strategy for polyadenylation in HTLV-I that is dependent on the RNA stem loop structure of the Rex response element. Cell 64:727–737, 1991.

  • Demonstration that 'NF-kB' represents a family of different transcription factors induced with distinct kinetics during T cell activation. Proc. Natl. Acad. Sci. USA 87:10028–10032, 1990.

  • Observation that the v-rel oncogene product encodes a kB binding protein that inhibits NF-kB function in mature cells. Cell 63:803–814, 1990.

  • Description of the role of kB-specific transcription factors in IL-2 gene activation. Science 244:457–460, 1989.

  • Demonstation that the same inducible transcription factor (NF-kB) activates the IL-2R-a gene and HIV LTR. Cell 53:827–836, 1988.

  • Description of HTLV-I Tax-mediated activation of the IL-2Ra kB enhancer. Science 141:1652–1655, 1988.

  • Description of studies demonstrating that HTLV-I Rex can functionally replace HIV-1 Rev Nature 335:738–740, 1988.

  • Description of the beta chain of the human IL-2 receptor complex. Nature 327:518–522, 1987.

  • Description of different binding properties for alpha and beta chain components of the human IL-2 receptor complex. J. Exp. Med. 166:1156–1161,1987.

  • Description of the activation of HIV-1 LTR by T cell mitogens and HTLV-Tax transactivator. Science 238:1575–1578, 1987.

  • Demonstration of deregulated expression of IL-2 receptor gene in HTLV-I infected leukemic T cells. Science 228:1215–1217, 1985.

  • Characterization of the structure of the human IL-2R-a gene. Science 230:633–639, 1985.

  • Description of the molecular cloning and characterization of the alpha chain of the human IL-2 receptor. Nature 311:626–631, 1984.

Gladstone Home | Cardiovascular Disease | Virology and Immunology | Neurological Disease | Administration | UCSF  
Contact Webmaster | Copyright © The J. David Gladstone Institutes | CMS created by Altrue.com | Admin.